



WHERE NATURE ENDS, NUREXONE BEGINS.

Regenerative medicine for central
nervous system injuries

NUREXONE BIOLOGIC

TSXV: NRX | OTCQB: NRXBF | FSE: J90

Q3 2026



DISCLAIMER

Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.

This presentation contains “forward-looking information” for purposes of applicable securities laws (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “seek”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our financial performance, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. This forward-looking information includes, among other things, statements relating to: expectations regarding industry trends, overall market growth rates and our growth rates and growth strategies; our business plans and strategies; expectations regarding growth; our competitive position in our industry.

Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, we caution you that actual results and developments (including our financial performance, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this presentation.

Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

United States Securities Laws:

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of NurExone Biologic Inc in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of NurExone Biologic Inc have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons," as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

NurExone does not declare and/or insure and/or imply on any specific result of any treatment which may be developed in the future based on the research and development process done or planned to be done by the Company.

SOME NERVES REPAIR NATURALLY. THE CENTRAL NERVOUS SYSTEM CAN'T



PERIPHERAL NERVES



CENTRAL NERVOUS SYSTEM

WHAT NEEDS TO BE DONE?

“The best way to restore function after spinal cord injury is to find ways to regenerate the [neural] connections that are broken.”



Reeve-Irvine Research Center

THE IDEA

**REGENERATE.
REWIRE.
RECOVER.**



NurExone is developing minimally invasive *exosome*-based regenerative therapies for central nervous system injuries.

THE CONSEQUENCE

A traumatic injury happens in a moment.



A FALL



A CRASH



A SPORTS INJURY

The damage can last a lifetime

~30,000 people in North America and Europe incur *acute spinal cord injuries (SCI)* each year.


Staggering healthcare, household and personal costs

- [18000 new cases in the US](#)
- [11,000 new cases in Europe](#)


NATURE'S TARGETED DELIVERY SYSTEM.

Exosomes are natural, acellular biological nanoparticles used in cell-to-cell communication.

- Tiny cell-free nanoparticles that can cross the Blood-Brain Barrier
- MSC exosomes have natural “homing” capabilities to sites of injury/inflammation.
- Loadable with therapeutic molecules to enhance their potential.
- Proprietary Master Cell Bank supports consistent, scalable production.
- Cell-free for universal applicability and potential off-the-shelf use.




ExoTherapy: Converting Exosomes to Therapeutics



Exosomes


**INHERENT
HEALING
PROPERTIES**

+



siRNA

**LOADING OF
THERAPEUTIC
MOLECULE**




ExoPTEN

**REGENERATIVE
THERAPY**

EXOPTEN: ONE INVESTIGATIONAL CANDIDATE.

MULTIPLE HIGH-IMPACT INDICATIONS UNDER STUDY.

- **SPINAL CORD** Functional + biological evidence
- **OPTIC NERVE** Retinal function + neuronal survival
- **FACIAL NERVE** Exploratory research




PRECLINICAL EVIDENCE - ExoPTEN for Acute Spinal Cord Injury

100%

of animals in the higher dose group regained **measurable walking** ability after minimally invasive treatment.

Gait recovery measured with CatWalk XT.




PRECLINICAL VIDEO EVIDENCE

High dose: 6/6 animals with measurable hind-limb motor function.

Structural Repair

MRI OF SPINE



Multiple High-Impact Indications

OPTIC NERVE DAMAGE (OND) - A SECOND CNS INDICATION.

\$2.5–4B

ESTIMATED COMBINED BASE PEAK TAM*

PACG

NAION / AION

MS-ON

Different diseases.

One shared target: the damaged optic nerve.

THE SAME REGENERATIVE THESIS

SPINAL CORD & OPTIC NERVE

PACG = Primary angle-closure glaucoma

NAION / AION = Nonarteric/Anterior Ischemic Optic Neuropathy

MS-ON = Multiple Sclerosis-Associated Optic Neuritis


PRECLINICAL EVIDENCE



IN COLLABORATION WITH SHEBA MEDICAL CENTER

75%

FUNCTIONAL RECOVERY



FUNCTION

Retinal response recovered toward healthy-eye levels.

CELL
SURVIVAL

ExoPTEN rescued retinal ganglion cells (p=0.0025).

STRUCTURE

Imaging showed healthier optic-nerve structure.

A SECOND VALUE ENGINE

SAME EXOSOMES - ANOTHER MARKET.


NurExone is building a U.S. based commercial platform for MSC-derived naïve exosomes — alongside its therapeutic development.

PRODUCE.

SUPPLY.

SCALE.

A nearer-term commercial opportunity built on the same exosome manufacturing foundation.



NAÏVE EXOSOMES FOR:

WELLNESS · LONGEVITY · AESTHETICS

MOVING FORWARD




2027 Objectives



Roadmap milestones are forward-looking and subject to change.

NurExone Biologic | TSXV: NRX · OTCQB: NRXBF · FSE: J90

CORPORATE STRUCTURE



STRONG TEAM INVESTED IN THE OUTCOME.

25%

FOUNDER OWNERSHIP

US\$20M+

RAISED SINCE INCEPTION

5

PATENT FAMILIES

FDA + EMA

ORPHAN DRUG DESIGNATIONS

2020

FOUNDED FROM TECHNION
& TAU



GLOBAL MEDIA MOMENTUM

THE NUREXONE STORY IS MOVING.



TV10

The Israeli Biotech Revolution
How Israeli companies are changing the global medical landscape

TV10
ECONOMY

10 כלכלה



advanced
THERAPIES


17 - 18 March 2026
ExCeL, London

**ADVANCING CELL AND
GENE THERAPIES**



44TH ANNUAL J.P. MORGAN
**Healthcare
Conference**

January 12-15, 2026
San Francisco, California



**ADVANCING
RNA**

Analytical/Quality | Manufacturing | Formulation | Outsourcing | Clinical Trials | Supply Chain | Watch Now

Guest Column | June 1, 2026

**From Exosomes To Nanodrugs: Advancing
Therapeutic Delivery For CNS Repair**

A conversation with Lior Shaltiel, Ph.D., CEO and director, NurExone Biologic

In this Q&A, Life Science Connect's Izzy Dininy caught up with Lior Shaltiel at NurExone Biologic to discuss the challenges associated with developing exosome-based therapeutics.

Advancing RNA



**FALLING
WALLS
SCIENCE
SUMMIT**

WHICH ARE
THE NEXT
WALLS
TO FALL?

LIOR SHALTIEL, PHD
CEO & DIRECTOR, NUREXONE BIOLOGIC

Falling Walls Science Summit

THE ELITE 50
Most-Known
Companies Shaping
2025




Galien Foundation
A conversation with Robin M. Welbers,
Director of Corporate Partnerships,
The Galien Foundation

Investing.com

CALCALIST

Yoram Drucker
Founder and Chairman of NurExone



BioProcess
International
by Informa

**Emerging
Modalities**

Laying the Groundwork
for Clinical and
Regulatory Success

by Lior Shaltiel and Tina Rogers

VISIBILITY IS BUILDING AS THE NEXT MILESTONES APPROACH.

Selected editorial coverage and platform visibility; distribution/profile platforms are shown separately.

Why NurExone?

- **HUGE UNMET NEED** : CNS injuries with limited natural regeneration
- **DIFFERENTIATED TECHNOLOGY**: Exosome + cargo + proprietary loading
- **PRECLINICAL EVIDENCE**: Functional and biological results across CNS models
- **MULTIPLE VALUE DRIVERS**: Therapeutics and commercial exosomes
- **MANUFACTURING**: U.S. GMP pathway + scalable exosome production

WHERE NATURE ENDS, NUREXONE BEGINS.

For more information please contact:
info@nurexone.com

TSXV: NRX | OTCQB: NRXBF | FSE: J90

NurExone is a preclinical biotechnology company. This presentation is for general information only and is not an offer or solicitation to buy or sell securities. Forward-looking statements involve risks and uncertainties. Preclinical results may not predict clinical outcomes.

